Grants and Contributions:
Title:
Pre-clinical Development of a Novel Personalized Treatment for B Cell Lymphomas
Agreement Number:
878946
Agreement Value:
$158,000.00
Agreement Date:
Jan 1, 2017 - Dec 31, 2018
Description:
Pacylex has discovered a biomarker that is lower in certain cancers than normal tissue and that confers sensitivity to our drug. With extensive proof-of-efficacies on our precision medicine strategy in vitro and in vivo in hand, this project enables the next steps of animal safety testing of our lead drug PCLX-001 and further mechanism of action studies to enable an investigative new drug (IND) Health Canada filing so we can eventually start Phase I trials, ideally in Edmonton, AB, Canada.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T5Y 3K7
Reference Number:
172-2018-2019-Q2-878946
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
825695588
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 92 days.
Amendment Date
Aug 17, 2018
Recipient's Legal Name:
Pacylex Pharmaceuticals Inc
Federal Riding Name:
Edmonton Manning
Federal Riding Number:
48016
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: